@article {Andreicae002293, author = {Ioana Andreica and Arturo Blazquez-Navarro and Jan Sokolar and Moritz Anft and Uta Kiltz and Stephanie Pfaender and Elena Vidal Blanco and Timm Westhoff and Nina Babel and Ulrik Stervbo and Xenofon Baraliakos}, title = {Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination}, volume = {8}, number = {2}, elocation-id = {e002293}, year = {2022}, doi = {10.1136/rmdopen-2022-002293}, publisher = {BMJ Specialist Journals}, abstract = {Objectives The effect of different modes of immunosuppressive therapy in autoimmune inflammatory rheumatic diseases (AIRDs) remains unclear. We investigated the impact of immunosuppressive therapies on humoral and cellular responses after two-dose vaccination.Methods Patients with rheumatoid arthritis, axial spondyloarthritis or psoriatic arthritis treated with TNFi, IL-17i (biological disease-modifying antirheumatic drugs, b-DMARDs), Janus-kinase inhibitors (JAKi) (targeted synthetic, ts-DMARD) or methotrexate (MTX) (conventional synthetic DMARD, csDMARD) alone or in combination were included. Almost all patients received mRNA-based vaccine, four patients had a heterologous scheme. Neutralising capacity and levels of IgG against SARS-CoV-2 spike-protein were evaluated together with quantification of activation markers on T-cells and their production of key cytokines 4 weeks after first and second vaccination.Results 92 patients were included, median age 50 years, 50\% female, 33.7\% receiving TNFi, 26.1\% IL-17i, 26.1\% JAKi (all alone or in combination with MTX), 14.1\% received MTX only. Although after first vaccination only 37.8\% patients presented neutralising antibodies, the majority (94.5\%) developed these after the second vaccination. Patients on IL17i developed the highest titres compared with the other modes of action. Co-administration of MTX led to lower, even if not significant, titres compared with b/tsDMARD monotherapy. Neutralising antibodies correlated well with IgG titres against SARS-CoV-2 spike-protein. T-cell immunity revealed similar frequencies of activated T-cells and cytokine profiles across therapies.Conclusions Even after insufficient seroconversion for neutralising antibodies and IgG against SARS-CoV-2 spike-protein in patients with AIRDs on different medications, a second vaccination covered almost all patients regardless of DMARDs therapy, with better outcomes in those on IL-17i. However, no difference of bDMARD/tsDMARD or csDMARD therapy was found on the cellular immune response.Data are available on reasonable request.}, URL = {https://rmdopen.bmj.com/content/8/2/e002293}, eprint = {https://rmdopen.bmj.com/content/8/2/e002293.full.pdf}, journal = {RMD Open} }